Breast cancer is number one in incidence and sixth in mortality among all cancers of women in China. Prior work identified positive consequences following diagnosis and treatment, including benefit finding among breast cancer survivors from Western countries. This study evaluated psychosocial correlates of benefit finding in breast cancer survivors in China. A total of 148 participants completed measures of coping, perceived stress, depressive symptoms, social support, and benefit finding. Results indicated that benefit finding was positively related to active coping and negatively related to depression. Future research may evaluate whether interventions to enhance active coping will improve outcomes among Chinese breast cancer survivors.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628715PMC
http://dx.doi.org/10.1177/1359105316637839DOI Listing

Publication Analysis

Top Keywords

benefit finding
20
breast cancer
20
cancer survivors
16
finding breast
12
psychosocial correlates
8
correlates benefit
8
survivors china
8
active coping
8
benefit
5
finding
5

Similar Publications

Importance: Three similar phase 3 randomized clinical trials have investigated PD-1/PD-L1 (programmed cell death 1 protein/programmed cell death 1 ligand 1) inhibitors in combination with platinum-based chemotherapy vs chemotherapy alone as first-line treatment for advanced urothelial carcinoma (IMvigor130, atezolizumab; KEYNOTE-361, pembrolizumab; and CheckMate901, nivolumab). Only CheckMate901 reported overall survival (OS) benefit for the combination. The reason for these inconsistent results is unclear.

View Article and Find Full Text PDF

Candidate Biomarker of Response to Immunotherapy In Small Cell Lung Cancer.

Curr Treat Options Oncol

January 2025

Department of Respiratory Medicine, Huzhou Central Hospital, Affiliated Central Hospital, Huzhou University, Huzhou, Zhejiang, China.

Small-cell lung cancer accounts for about 15% of lung cancers with an extremely poor prognosis. The incorporation of immunotherapy to platinum-based chemotherapy offers sustained overall survival benefits and become the standard for the first-line setting of extensive-stage small-cell lung cancer. However, only a limited number of patients derive prolonged benefits.

View Article and Find Full Text PDF

CTCNet: a fine-grained classification network for fluorescence images of circulating tumor cells.

Med Biol Eng Comput

January 2025

Anhui BioX-Vision Biological Technology Co., Ltd, Hefei, 230031, Anhui, China.

The identification and categorization of circulating tumor cells (CTCs) in peripheral blood are imperative for advancing cancer diagnostics and prognostics. The intricacy of various CTCs subtypes, coupled with the difficulty in developing exhaustive datasets, has impeded progress in this specialized domain. To date, no methods have been dedicated exclusively to overcoming the classification challenges of CTCs.

View Article and Find Full Text PDF

Typing Arctic and Africa-2 clades of rabies virus using clade-defining single nucleotide polymorphisms.

Arch Microbiol

January 2025

Department of Biochemistry, Division of Biological Sciences, Indian Institute of Science, Bangalore, India.

Rabies is a deadly neurotropic, zoonotic disease with a mortality rate of 100% after symptoms appear. Rabies virus (RABV) is the primary cause of rabies disease in humans, and it mainly spreads via dog bites in developing countries. Over the course of RABV evolution, multiple RABV variants, called clades, have emerged.

View Article and Find Full Text PDF

Background: Guidelines specify steroids as therapy for acute exacerbation of chronic obstructive pulmonary disease (AECOPD). However, the duration of survival benefit associated with steroids and the optimal dosage of nebulized budesonide (NB) during hospitalization remain unclear.

Methods: We conducted a retrospective study of hospitalized AECOPD patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!